You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Mitochondrial TAT-DNA repair proteins for treatment of insulin resistance
SBC: EXSCIEN CORPORATION Topic: NIDDKDESCRIPTION provided by applicant Insulin resistance IR also known as metabolic syndrome is tied to obesity and is associated with numerous modern health problems including the growing problems of type diabetes and cardiovascular disease The growing health economic and social burdens of these conditions calls for the need to develop drug treatments for IR We know from multiple lines of ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes
SBC: CUMBERLAND PHARMACEUTICALS, INC. Topic: 300DESCRIPTION provided by applicant Problem Lower gastrointestinal bleeding is a significant medical problem in the United States accounting for more than hospital admissions and tens of billions of dollars of healthcare spending annually It is common for bleeding from a single site to stop and restart multiple times The three modalities now used to diagnose and locate gastrointestina ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Macromolecule Crystallization Screening Results Analysis
SBC: iXpressGenes, Inc. Topic: 100Project Summary Crystallization followed by subsequent structure determination is a major step in understanding the structure function relationship of macromolecules Understanding macromolecule structure has become a key part in the development of new pharmaceuticals and is a major area of NIH research Crystallization however is also the rate limiting step despite technological efforts to a ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care Applications
SBC: GENECAPTURE, INC. Topic: CBD15C001The modern warfighter faces the constant threat of endemic infections, multi-drug resistant bacteria and Biological Warfare Agents. In order to provide accurate front-line treatment that will curtail the overuse of antibiotics, a rapid and robust molecula
STTR Phase I 2016 Department of DefenseOffice for Chemical and Biological Defense -
Innovative Mitigation of Radiation Effects in Advanced Technology Nodes
SBC: RELIABLE MICROSYSTEMS LLC Topic: DTRA16A003Establish a radiation-aware analysis capability in a commercial EDA design flow that will enable first-pass success in radiation-hardened by design (RHBD) for DoD ASICs in much the same way that existing EDA design suites ensure first pass functionality and performance success of complex ASICs destined for commercial applications. Layout-aware, calibrated single-event radiation models that captur ...
STTR Phase I 2016 Department of DefenseDefense Threat Reduction Agency -
Islet Protection from Hypoxia Posttransplant
SBC: BIOINVENTIONS, LLC Topic: NIDDKDESCRIPTION (provided by applicant): Islet transplantation (ITx), especially with the emerging potential of xenotransplantation, holds significant promise for the treatment of type 1 diabetes (T1D). There are, however, major challenges that remain prior to its larger scale, cost-effective application. Hypoxia is a leading stress post-transplantation and is estimated to cause the death of approxima ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Optimization of Protein Therapeutic Formulations
SBC: SOLUBLE THERAPEUTICS, INC Topic: NIGMSDESCRIPTION (provided by applicant): This proposal involves the development and validation of a novel approach to improve and accelerate the discovery of biopharmaceuticals (i.e. vaccines, monoclonal antibodies and other therapeutic proteins). Biopharmaceuticals are used to treat a variety of infectious and chronic diseases. The proposed research is intended to establish a new paradigm for rapidly ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Fluorescence Intensity-Based Scoring of Macromolecule Crystallization Plates
SBC: iXpressGenes, Inc. Topic: NIGMSDESCRIPTION (provided by applicant): Crystallization, followed by subsequent structure determination, is a major step in understanding the structure-function relationship of macromolecules. Understanding macromolecule structure has become a key part in the development of new pharmaceuticals, and is a major area of NIH research. Crystallization however is also the rate limiting step, despite techn ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
An Advanced Biosensor for Molecular Interaction Studies
SBC: MOLECULAR SENSING, INC. Topic: NIGMSDESCRIPTION (provided by applicant): Molecular interactions are central to the understanding of basic biology and cellular function, are paramount to all molecular assays (research and in vitro diagnostics), are essential in biomarker discovery and critical toward evaluating therapeutics. However, the tools available to quantify these interactions have limitations, in so far as they either rely up ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Novel Methods for Dissolving Blood Clots
SBC: TRANSLATIONAL SCIENCES INC Topic: NHLBIDESCRIPTION (provided by applicant): Cardiovascular disease is the leading cause of death worldwide. Current therapies for cardiovascular disease are associated with partial success, restricted access, delays, possible neurotoxicity and other important limitations. Our goal is to develop a novel therapeutic agent that is safer and more effective at dissolving the blood clots (thrombi) that cause h ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health